SYDNEY, Sept. 29, 2014 (GLOBE NEWSWIRE) -- Novogen Ltd. (ASX: NRT, NASDAQ: NVGN)
Graham Kelly PhD, CEO & Chairman attended the Rodman &
Renshaw 16th Annual Global Investment Conference where he was
interviewed by Ed Kershen, Equities.com providing an overview and
history of Novogen Ltd. and CanTx Inc., including growth prospects
brought about by new and unique technologies of Novogen Ltd and
CanTx Inc. Novogen and CanTx new technologies as Dr Kelly explains
have the potential to become the "go to" drugs for first line
therapy in particular cancers.
Please follow the link;
http://www.equities.com/media-gallery/329-dr-graham-kelly-chairman-and-ceo-novogen-
ltd?category_id=73
About Novogen Limited
Novogen is a public, Australian drug-development company whose
shares trade on both the Australian Securities Exchange ('NRT') and
NASDAQ ('NVGN'). The Novogen Group includes a New Haven CT - based
joint venture company, CanTx Inc, with Yale University.
Novogen has two main drug technology platforms:
super-benzopyrans (SBPs) and anti- tropomyosins (ATMs). SBP
compounds have been created to kill the full range of cells within
a tumor, but particularly the cancer stem cells. The ATM compounds
target the microfilament component of the cancer cell and when used
in conjunction with standard anti- microtubular drugs, result in
comprehensive and fatal destruction of the cancer cell's
cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites,
prostate cancer, neural cancers (glioblastoma, neuroblastoma) and
melanoma are the key clinical indications being pursued, with the
ultimate objective of employing both technologies as a unified
approach to first-line therapy.
About CanTx
CanTx Inc is a private biotechnology company based in New Haven,
Connecticut, and established as a joint venture between Novogen and
Yale University. CanTx is dedicated to the development of
anti-cancer drugs for the treatment of ovarian cancer.
Further information is available on the Company's website,
www.novogen.com And www.can-tx.com
CONTACT: Corporate Contact
Executive Chairman & CEO Novogen Group
Graham.Kelly@novogen.com
+61 (0) 2 9472 4100
Media Enquiries
Operations Manager
Cristyn.Humphreys@novogen.com
+61 (0) 2 9472 4111
Investors Enquiries
Executive Chairman & CEO
Novogen Group
Graham.Kelly@novogen.com
+61 (0) 2 9472 4100